The natural history of multiple system atrophy: a prospective European cohort study

Wenning, 2004, Multiple system atrophy, Lancet Neurol, 3, 93, 10.1016/S1474-4422(03)00662-8 Quinn, 1989, Multiple system atrophy—the nature of the beast, J Neurol Neurosurg Psychiatry, 78, 10.1136/jnnp.52.Suppl.78 Gilman, 1999, Consensus statement on the diagnosis of multiple system atrophy, J Neurol Sci, 163, 94, 10.1016/S0022-510X(98)00304-9 Wenning, 1994, Clinical features and natural history of multiple system atrophy. An analysis of 100 cases, Brain, 117, 835, 10.1093/brain/117.4.835 Colosimo, 2011, Nonmotor presentations of multiple system atrophy, Nature Rev Neurol, 7, 295, 10.1038/nrneurol.2011.5 Jecmenica-Lukic, 2012, Premotor signs and symptoms of multiple system atrophy, Lancet Neurol, 11, 361, 10.1016/S1474-4422(12)70022-4 Bensimon, 2009, Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study, Brain, 132, 156, 10.1093/brain/awn291 Payan, 2011, Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS—Parkinson Plus Scale, PLoS One, 6, e22293, 10.1371/journal.pone.0022293 May, 2007, Potential outcome measures and trial design issues for multiple system atrophy, Mov Disord, 22, 2371, 10.1002/mds.21734 Seppi, 2005, Progression of parkinsonism in multiple system atrophy, J Neurol, 252, 91, 10.1007/s00415-005-0617-2 Klockgether, 1998, The natural history of degenerative ataxia: a retrospective study in 466 patients, Brain, 121, 589, 10.1093/brain/121.4.589 Muller, 2000, Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study, Neurology, 55, 888, 10.1212/WNL.55.6.888 O'Sullivan, 2008, Clinical outcomes of progressive supranuclear palsy and multiple system atrophy, Brain, 131, 1362, 10.1093/brain/awn065 Schrag, 2008, Survival in multiple system atrophy, Mov Disord, 23, 294, 10.1002/mds.21839 Watanabe, 2002, Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients, Brain, 125, 1070, 10.1093/brain/awf117 Wenning, 1997, Multiple system atrophy: a review of 203 pathologically proven cases, Mov Disord, 12, 133, 10.1002/mds.870120203 Kollensperger, 2010, Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry, Mov Disord, 25, 2604, 10.1002/mds.23192 Wenning, 2004, Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS), Mov Disord, 19, 1391, 10.1002/mds.20255 Stefanova, 2008, Rasagiline is neuroprotective in a transgenic model of multiple system atrophy, Exp Neurol, 210, 421, 10.1016/j.expneurol.2007.11.022 Stefanova, 2007, Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy, Mov Disord, 22, 2196, 10.1002/mds.21671 Ubhi, 2008, Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy, Neuroreport, 19, 1271, 10.1097/WNR.0b013e32830b3661 Wenning, 2009, Recent developments in multiple system atrophy, J Neurol, 256, 1791, 10.1007/s00415-009-5173-8 Dodel, 2010, Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial), Mov Disord, 25, 97, 10.1002/mds.22732 Holmberg, 2007, Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study, Mov Disord, 22, 1138, 10.1002/mds.21501 Geser, 2006, Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG), Mov Disord, 21, 179, 10.1002/mds.20678 Geser, 2005, The European Multiple System Atrophy-Study Group (EMSA-SG), J Neural Transm, 112, 1677, 10.1007/s00702-005-0328-y Hoehn, 1967, Parkinsonism: onset, progression and mortality, Neurology, 17, 427, 10.1212/WNL.17.5.427 Schwab, 1969, Projection technique for evaluating surgery in Parkinson's disease, 152 Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 Group, 1990, EuroQol-a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9 Suarez, 1999, The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms, Neurology, 52, 523, 10.1212/WNL.52.3.523 Kollensperger, 2007, Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment, Eur J Neurol, 14, 66, 10.1111/j.1468-1331.2006.01554.x van Buuren, 2007, Multiple imputation of discrete and continuous data by fully conditional specification, Stat Methods Med Res, 16, 219, 10.1177/0962280206074463 Collett, 2003 Spencer, 1992, Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease, N Engl J Med, 327, 1541, 10.1056/NEJM199211263272201 Ullman, 2012, Deep brain stimulation response in pathologically confirmed cases of multiple system atrophy, Parkinsonism Relat Disord, 18, 86, 10.1016/j.parkreldis.2011.09.008 Berciano, 2002, Presynaptic parkinsonism in multiple system atrophy mimicking Parkinson's disease: a clinicopathological case study, Mov Disord, 17, 812, 10.1002/mds.10190 Tarsy, 2003, Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy, Neurology, 61, 247, 10.1212/01.WNL.0000073986.74883.36 Lezcano, 2004, Parkinson's disease-like presentation of multiple system atrophy with poor response to STN stimulation: a clinicopathological case report, Mov Disord, 19, 973, 10.1002/mds.20108 Talmant, 2006, Subthalamic stimulation in a patient with multiple system atrophy: a clinicopathological report, Rev Neurol, 162, 363, 10.1016/S0035-3787(06)75023-8 Chou, 2004, Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Case report, J Neurosurg, 100, 553, 10.3171/jns.2004.100.3.0553 Schulz, 1994, Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT, J Neurol Neurosurg Psychiatry, 57, 1047, 10.1136/jnnp.57.9.1047 Lipp, 2009, Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure, Arch Neurol, 66, 742, 10.1001/archneurol.2009.71 Iodice, 2012, Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests, J Neurol Neurosurg Psychiatry, 83, 453, 10.1136/jnnp-2011-301068 Lee, 1994, Clinical observations on the rate of progression of idiopathic parkinsonism, Brain, 117, 501, 10.1093/brain/117.3.501 Poewe, 1998, The natural history of Parkinson's disease, Ann Neurol, 44, S1, 10.1002/ana.410440703 Schrag, 2006, Health-related quality of life in multiple system atrophy, Mov Disord, 21, 809, 10.1002/mds.20808 Schrag, 2007, Measuring health-related quality of life in MSA: the MSA-QoL, Mov Disord, 22, 2332, 10.1002/mds.21649 Schrag, 2010, A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy, Mov Disord, 25, 1077, 10.1002/mds.22794 Winter, 2011, Health-related quality of life in multiple system atrophy and progressive supranuclear palsy, Neurodegener Dis, 8, 438, 10.1159/000325829